A Phase IC Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Cognitive Outcomes of BI 409306 in Patients with Mild-to-Moderate Schizophrenia

INTRODUCTION: This randomized, double-blind, parallel-group study investigated the safety, tolerability, pharmacokinetics (PK), and cognitive outcomes of BI 409306—a selective phosphodiesterase 9A (PDE9A) inhibitor—in patients with schizophrenia. METHODS: Patients with mild-to-moderate schizophrenia...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, David, Daniels, Kristen, Pichereau, Solen, Sand, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990500/
https://www.ncbi.nlm.nih.gov/pubmed/29177699
http://dx.doi.org/10.1007/s40120-017-0085-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990500/
https://www.ncbi.nlm.nih.gov/pubmed/29177699
http://dx.doi.org/10.1007/s40120-017-0085-5

Ejemplares similares